Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
OKYO Pharma Limited Sponsored ADR ( (OKYO) ) has provided an announcement.
On February 11, 2026, OKYO Pharma announced it has shifted its At-The-Market equity offering facility to Leerink Partners LLC, replacing its prior arrangement with B. Riley Securities Inc. Leerink, a healthcare-focused investment bank, will act as exclusive sales agent, earning a 3.0% commission on gross proceeds from any common shares sold into the market under the program.
Management said the move is intended to enhance financial flexibility as the company advances its clinical pipeline, including the planned Phase 2b/3 study of lead candidate urcosimod for neuropathic corneal pain. By keeping an ATM facility in place, OKYO can raise capital opportunistically at prevailing market prices with potentially less market disruption, supporting ongoing development and corporate objectives without committing to a large, fixed equity raise.
The most recent analyst rating on (OKYO) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on OKYO Pharma Limited Sponsored ADR stock, see the OKYO Stock Forecast page.
Spark’s Take on OKYO Stock
According to Spark, TipRanks’ AI Analyst, OKYO is a Neutral.
The score is held down primarily by weak fundamentals (pre-revenue, ongoing losses, negative free cash flow, and negative equity) despite improved 2025 cost and cash-burn trends and zero debt. Technicals are a meaningful offset with strong momentum above key moving averages, while valuation remains challenged due to negative earnings and no indicated dividend yield.
To see Spark’s full report on OKYO stock, click here.
More about OKYO Pharma Limited Sponsored ADR
OKYO Pharma Limited is a clinical-stage biopharmaceutical company listed on the Nasdaq Capital Market, focused on developing innovative therapies for neuropathic corneal pain and inflammatory eye diseases. The company is advancing novel ocular drug candidates, including its flagship molecule urcosimod, which recently completed a successful Phase 2 trial in neuropathic corneal pain and is moving into a larger Phase 2b/3 study.
Average Trading Volume: 199,861
Technical Sentiment Signal: Sell
Current Market Cap: $72.21M
Learn more about OKYO stock on TipRanks’ Stock Analysis page.